- Prespecified Analysis of Expanded Safety Outcomes of Ravulizumab in IgAN from the SANCTUARY Trial
10:00 AM - 12:00 PM
Prespecified Analysis of Expanded Safety Outcomes of Ravulizumab in IgAN from the SANCTUARY Trial
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Lipoic Acid Supplementation Is Associated with Proteinuria in a Randomized Controlled Trial of Patients with Progressive Multiple Sclerosis
10:00 AM - 12:00 PM
Lipoic Acid Supplementation Is Associated with Proteinuria in a Randomized Controlled Trial of Patients with Progressive Multiple Sclerosis
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Absolute Proteinuria over Time with Nefecon vs. Placebo in Patients with IgAN: Results from the Phase 3 NefIgArd Trial
10:00 AM - 12:00 PM
Absolute Proteinuria over Time with Nefecon vs. Placebo in Patients with IgAN: Results from the Phase 3 NefIgArd Trial
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Sparsentan Slows the Loss of Kidney Function in Patients with IgAN: Post Hoc Analyses of the Phase 3 PROTECT Study
10:00 AM - 12:00 PM
Sparsentan Slows the Loss of Kidney Function in Patients with IgAN: Post Hoc Analyses of the Phase 3 PROTECT Study
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Design of a Single-Center, Phase 1b Trial Evaluating the Efficacy and Safety of First-in-Class Myeloid-Directed ONT01 as a Treatment for Lupus Nephritis
10:00 AM - 12:00 PM
Design of a Single-Center, Phase 1b Trial Evaluating the Efficacy and Safety of First-in-Class Myeloid-Directed ONT01 as a Treatment for Lupus Nephritis
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- PROTECT Post Hoc Analysis: Efficacy of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients (Pts) with IgAN ≤12 mo vs. >12 mo from Kidney Biopsy
10:00 AM - 12:00 PM
PROTECT Post Hoc Analysis: Efficacy of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients (Pts) with IgAN ≤12 mo vs. >12 mo from Kidney Biopsy
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Safety, Tolerability, and Efficacy of Mezagitamab (TAK-079) as Add-On to Standard-of-Care Therapy in Individuals with Primary IgAN: Week 96 Data from an Open-Label Phase 1b Study
10:00 AM - 12:00 PM
Safety, Tolerability, and Efficacy of Mezagitamab (TAK-079) as Add-On to Standard-of-Care Therapy in Individuals with Primary IgAN: Week 96 Data from an Open-Label Phase 1b Study
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Effect of Sparsentan (SPAR) on Proteinuria and Urinary Inflammatory and Profibrotic Biomarkers by Baseline Proteinuria Strata in SPARTAN Study Participants with IgAN
10:00 AM - 12:00 PM
Effect of Sparsentan (SPAR) on Proteinuria and Urinary Inflammatory and Profibrotic Biomarkers by Baseline Proteinuria Strata in SPARTAN Study Participants with IgAN
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Evaluation of Cardiovascular Risk Factors, Structure, and Function in an Interim Analysis of the SPARTAN Study: Sparsentan as First-Line Treatment of Incident Patients with IgAN
10:00 AM - 12:00 PM
Evaluation of Cardiovascular Risk Factors, Structure, and Function in an Interim Analysis of the SPARTAN Study: Sparsentan as First-Line Treatment of Incident Patients with IgAN
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Efficacy and Safety of Iptacopan in Patients (Pts) from East Asia with IgAN: Interim Results from the Phase 3 APPLAUSE-IgAN Trial
10:00 AM - 12:00 PM
Efficacy and Safety of Iptacopan in Patients (Pts) from East Asia with IgAN: Interim Results from the Phase 3 APPLAUSE-IgAN Trial
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Efficacy and Safety of ALXN2050 in IgAN: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
10:00 AM - 12:00 PM
Efficacy and Safety of ALXN2050 in IgAN: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Povetacicept for IgAN: Design of a Phase 3 Randomized, Placebo-Controlled Study
10:00 AM - 12:00 PM
Povetacicept for IgAN: Design of a Phase 3 Randomized, Placebo-Controlled Study
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Long-Term Stabilization of Kidney Function Regardless of Baseline eGFR and Urine Protein-to-Creatinine Ratio (UPCR) in Patients with IgAN: Subgroup Analyses from the Phase 1/2 Trial of Zigakibart
10:00 AM - 12:00 PM
Long-Term Stabilization of Kidney Function Regardless of Baseline eGFR and Urine Protein-to-Creatinine Ratio (UPCR) in Patients with IgAN: Subgroup Analyses from the Phase 1/2 Trial of Zigakibart
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Efficacy of Ravulizumab on Proteinuria Response by Baseline Proteinuria or eGFR: Post Hoc Analysis of the SANCTUARY Trial
10:00 AM - 12:00 PM
Efficacy of Ravulizumab on Proteinuria Response by Baseline Proteinuria or eGFR: Post Hoc Analysis of the SANCTUARY Trial
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Effect of Hydroxychloroquine on Proteinuria and Inflammatory Markers in Chronic Glomerulopathy: A Randomized Controlled Trial (HCQ-CGN Trial)
10:00 AM - 12:00 PM
Effect of Hydroxychloroquine on Proteinuria and Inflammatory Markers in Chronic Glomerulopathy: A Randomized Controlled Trial (HCQ-CGN Trial)
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Evaluation of Hematuria in Patients Treated with Ravulizumab in the Phase 2 SANCTUARY Trial
10:00 AM - 12:00 PM
Evaluation of Hematuria in Patients Treated with Ravulizumab in the Phase 2 SANCTUARY Trial
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Pharmacokinetic/Pharmacodynamic Modeling to Support 70 mg Sefaxersen Dose Selection for Phase 3 (IMAgINATION) in IgAN
10:00 AM - 12:00 PM
Pharmacokinetic/Pharmacodynamic Modeling to Support 70 mg Sefaxersen Dose Selection for Phase 3 (IMAgINATION) in IgAN
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Urine IP-10-Guided Preemptive Immunosuppression in Lupus Nephritis: A Multicenter Randomized Controlled Trial
10:00 AM - 12:00 PM
Urine IP-10-Guided Preemptive Immunosuppression in Lupus Nephritis: A Multicenter Randomized Controlled Trial
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Comparative Outcomes of Rituximab- vs. Cyclophosphamide-Based Induction Regimens in ANCA-Associated Renal Vasculitis: Systematic Review and Meta-Analysis
10:00 AM - 12:00 PM
Comparative Outcomes of Rituximab- vs. Cyclophosphamide-Based Induction Regimens in ANCA-Associated Renal Vasculitis: Systematic Review and Meta-Analysis
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Single-Arm, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy of Low-Dosage Administration of Telitacicept in IgAN
10:00 AM - 12:00 PM
Single-Arm, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy of Low-Dosage Administration of Telitacicept in IgAN
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Comparison of the Efficacy of Rituximab and Tacrolimus in Patients with High-Titer Phospholipase A2 Receptor (PLA2R) Antibody-Associated Membranous Nephropathy
10:00 AM - 12:00 PM
Comparison of the Efficacy of Rituximab and Tacrolimus in Patients with High-Titer Phospholipase A2 Receptor (PLA2R) Antibody-Associated Membranous Nephropathy
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Meta-Analysis of Safety and Efficacy of Reduced Glucocorticoid Induction Regimens in ANCA-Associated Vasculitis
10:00 AM - 12:00 PM
Meta-Analysis of Safety and Efficacy of Reduced Glucocorticoid Induction Regimens in ANCA-Associated Vasculitis
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Efficacy and Safety of ALXN2050 (Vemircopan) in Lupus Nephritis: Results of a Phase 2 Trial
10:00 AM - 12:00 PM
Efficacy and Safety of ALXN2050 (Vemircopan) in Lupus Nephritis: Results of a Phase 2 Trial
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Anifrolumab Use in Patients with Lupus Nephritis Is Associated with Decreased Progression to ESRD
10:00 AM - 12:00 PM
Anifrolumab Use in Patients with Lupus Nephritis Is Associated with Decreased Progression to ESRD
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Design of a Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis
10:00 AM - 12:00 PM
Design of a Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Renin-Angiotensin System Inhibitor (RASi) Use and Atrasentan in IgAN: Post Hoc Analysis from the ALIGN Trial
10:00 AM - 12:00 PM
Renin-Angiotensin System Inhibitor (RASi) Use and Atrasentan in IgAN: Post Hoc Analysis from the ALIGN Trial
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Effect of Avacopan on Kidney Function in Maintenance Therapy of ANCA-Associated Vasculitis: Single-Center Experience in Japan
10:00 AM - 12:00 PM
Effect of Avacopan on Kidney Function in Maintenance Therapy of ANCA-Associated Vasculitis: Single-Center Experience in Japan
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Adaptive Phase 2/3 Study for PCS499 (499) in Patients with FSGS
10:00 AM - 12:00 PM
Adaptive Phase 2/3 Study for PCS499 (499) in Patients with FSGS
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Preservation of Humoral Immunity and Response to Vaccination and Infection in Felzartamab-Treated Patients with IgAN: Data from the Phase 2 IGNAZ Study
10:00 AM - 12:00 PM
Preservation of Humoral Immunity and Response to Vaccination and Infection in Felzartamab-Treated Patients with IgAN: Data from the Phase 2 IGNAZ Study
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Baseline Characteristics of ASSIST: Phase 2 Crossover Trial of Atrasentan in Adults with IgAN on SGLT2 Inhibitors
10:00 AM - 12:00 PM
Baseline Characteristics of ASSIST: Phase 2 Crossover Trial of Atrasentan in Adults with IgAN on SGLT2 Inhibitors
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Interim Phase 1 Study Results of ADX-038: A Novel siRNA Against Complement Factor B, and Next Steps in IgAN and C3 Glomerulopathy (C3G)
10:00 AM - 12:00 PM
Interim Phase 1 Study Results of ADX-038: A Novel siRNA Against Complement Factor B, and Next Steps in IgAN and C3 Glomerulopathy (C3G)
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- First-in-Human Trial of XH-S003, a Small Molecule Complement Factor B Inhibitor, Shows Favorable Pharmacokinetics and Complete Suppression of Alternative Pathway in Healthy Volunteers in Australia
10:00 AM - 12:00 PM
First-in-Human Trial of XH-S003, a Small Molecule Complement Factor B Inhibitor, Shows Favorable Pharmacokinetics and Complete Suppression of Alternative Pathway in Healthy Volunteers in Australia
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Effect of Selective Endothelin A Receptor Antagonists on Proteinuria in IgAN: Systematic Review and Meta-Analysis
10:00 AM - 12:00 PM
Effect of Selective Endothelin A Receptor Antagonists on Proteinuria in IgAN: Systematic Review and Meta-Analysis
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Heterogeneity in Randomized Clinical Trials Regarding Desmopressin Use Before Kidney Biopsy to Prevent Bleeding
10:00 AM - 12:00 PM
Heterogeneity in Randomized Clinical Trials Regarding Desmopressin Use Before Kidney Biopsy to Prevent Bleeding
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Pegcetacoplan for 52 Weeks Maintains Proteinuria Reduction Regardless of Immunosuppressant Use or Nephrotic-Range Proteinuria at Baseline: VALIANT Subgroup Analysis
10:00 AM - 12:00 PM
Pegcetacoplan for 52 Weeks Maintains Proteinuria Reduction Regardless of Immunosuppressant Use or Nephrotic-Range Proteinuria at Baseline: VALIANT Subgroup Analysis
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Update to the Long-Term Efficacy and Safety of Iptacopan in C3 Glomerulopathy: 39-Month Phase 2 Extension Study Data
10:00 AM - 12:00 PM
Update to the Long-Term Efficacy and Safety of Iptacopan in C3 Glomerulopathy: 39-Month Phase 2 Extension Study Data
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy: C3G Extension Trial Interim Results from the Phase 3 APPEAR-C3G Patients
10:00 AM - 12:00 PM
Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy: C3G Extension Trial Interim Results from the Phase 3 APPEAR-C3G Patients
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Sparsentan (SPAR) in Participants with FSGS and Collagen Type IV Alpha 3-5 Chain (COL4A3-5) Variants
10:00 AM - 12:00 PM
Sparsentan (SPAR) in Participants with FSGS and Collagen Type IV Alpha 3-5 Chain (COL4A3-5) Variants
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- XH-S003, a Small Molecule Complement Factor B Inhibitor, Shows Favorable Pharmacokinetics and Complete Suppression of an Alternative Pathway at Well-Tolerated Doses in Healthy Volunteers in China
10:00 AM - 12:00 PM
XH-S003, a Small Molecule Complement Factor B Inhibitor, Shows Favorable Pharmacokinetics and Complete Suppression of an Alternative Pathway at Well-Tolerated Doses in Healthy Volunteers in China
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Establishment of a Rapid and Automatic Eli-TR Chimeric Antigen Receptor T Cell Manufacturing and Release Platform for the Treatment of Autoimmune Diseases, Including Membranous Nephropathy (MN)
10:00 AM - 12:00 PM
Establishment of a Rapid and Automatic Eli-TR Chimeric Antigen Receptor T Cell Manufacturing and Release Platform for the Treatment of Autoimmune Diseases, Including Membranous Nephropathy (MN)
November 07, 2025 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
